The HER2-CD3-Fc bsAb-mediated antitumor effect is highly specific and strictly dependent on its binding to the HER2 epitope, as tumor cells lacking HER2 become resistant to the bsAb-induced T cell cytotoxicity. Here, ERBB2 is linked to neoplasm.